Therapeutic Drug Use for CKD Patients

eGFR,albuminuria

Chronic kidney disease (CKD), characterized as renal dysfunction, is recognized as a major
 public health problem with high morbidity and mortality worldwide. This study aimed to
 analyze the common drug use and combinations of different stages and types of CKD patients.
 The study is a multicenter retrospective study involving three hospitals. Investigators
 reviewed and analyzed all patients diagnosed with chronic kidney disease from July 1, 2020 to
 June 30, 2022. Chronic kidney disease was defined as eGFR less than 60 mL/min per 1·73 m(2)
 or the presence of albuminuria. The study selected seven types of drugs based on hospital
 electronic medical record data, including β Receptor blockers, angiotensin converting enzyme
 inhibitor blockers, angiotensin II receptors, DPP-4 inhibitors, GLP-1 receptor agonists,
 SGLT2 inhibitors, and calcium channel blockers. Chi-square test, Mann-Whitney Wilcoxon test,
 and Kruskal Wallis test will be used for statistical analysis. The main purpose of this study
 is to provide evidence for promoting rational drug use in CKD patients by describing the drug
 use. The secondary purpose of the study is to explore the efficacy, safety and economy of
 SGLT-2 inhibitors in diabetes nephropathy (DN).